DPhil Supervisor Profile
CBE FMedSci FRCP
Professor of Cancer Medicine
- Consultant Physician
In collaboration with Dr Rachel Midgley, Oncology Clinical Trials Office, we have conducted a series of international adjuvant trials of chemotherapy for colorectal cancer. In parallel, we have established a biorepository of tissue and constitutional DNA (n=3500) which has allowed us to collaborate with Ian Tomlinson to generate a number of cancer susceptibility SNPs and commercial partners to characterise a prognostic mRNA signature which assists in selection of patients for chemotherapy. We are currently developing biomarkers for the anti-angiogenic agent bevacizumab.
Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial.
Kerr RS. et al, (2016), Lancet Oncol, 17, 1543 - 1557
Association analyses identify 31 new risk loci for colorectal cancer susceptibility.
Law PJ. et al, (2019), Nat Commun, 10
Confirmation that somatic mutations of beta-2 microglobulin correlate with a lack of recurrence in a subset of stage II mismatch repair deficient colorectal cancers from the QUASAR trial.
Barrow P. et al, (2019), Histopathology
Oxford Textbook of Cancer Biology
Pezzella F. et al, (2019)
Universal screening for Lynch syndrome in a large consecutive cohort of Chinese colorectal cancer patients: High prevalence and unique molecular features.
Jiang W. et al, (2019), Int J Cancer, 144, 2161 - 2168
An FBXW7-ZEB2 axis links EMT and tumour microenvironment to promote colorectal cancer stem cells and chemoresistance.
Li N. et al, (2019), Oncogenesis, 8